Atopic DermatitisPhase 3AD UpNCT03568318
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 3 study testing Upadacitinib and Topical corticosteroids (TCS) in people with Atopic Dermatitis, run by AbbVie at 193 sites in 24 countries.
Trial summary
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. Read more about this study
- Who is it for?
- Ages 12 to 75 years
- Conditions the study is for
- Atopic Dermatitis
- What is being tested?
- Upadacitinib and Topical corticosteroids (TCS)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,533 participants
- Where
- 193 sitesin 24 countries
- Study dates
- 9 Aug 2018to 23 Oct 2030
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age
- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline Visit and subject meets Hanifin and Rajka criteria.
- Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, ≥ 10% of body surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus numerical rating scale (NRS) ≥ 4.
- Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
- Documented history of inadequate response to topical corticosteroids or topical calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to Baseline Visit
Who cannot join
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Trial locations and contacts
193 sites in 24 countries.
193 sites in 24 countries
United States59 sites
ORA, Inc. /ID# 202824
Andover, Massachusetts, 01810
Arlington Research Center, Inc /ID# 200559
Arlington, Texas, 76011
Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822
Aurora, Colorado, 80045-2517
Bakersfield Derma & Skin Cance /ID# 200892
Bakersfield, California, 93309
Mosaic Dermatology /ID# 200553
Beverly Hills, California, 90211
Bexley Dermatology Research /ID# 200899
Bexley, Ohio, 43209-2422
Total Skin and Beauty Derm Ctr /ID# 200548
Birmingham, Alabama, 35205
Clinical Research Center AL /ID# 201865
Birmingham, Alabama, 35209-6802
ACCEL Research Sites /ID# 213364
Birmingham, Alabama, 35218
Clearlyderm Dermatology /ID# 207709
Boca Raton, Florida, 33428
Skin Care Research, LLC /ID# 200812
Boca Raton, Florida, 33486-2269
Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628
Boise, Idaho, 83713
Tufts Medical Center /ID# 200570
Boston, Massachusetts, 02111-1552
Beth Israel Deaconess Medical Center /ID# 200545
Boston, Massachusetts, 02215-5400
Colorado Center for Dermatology, PLLC /ID# 203626
Centennial, Colorado, 80111-1724
Clin Res Inst of Michigan, LLC /ID# 208020
Chesterfield, Michigan, 48047
Northwestern University Feinberg School of Medicine /ID# 201646
Chicago, Illinois, 60611-2927
Michigan Center for Research Company /ID# 200560
Clarkston, Michigan, 48346
Clinical Research of West Florida, Inc /ID# 203643
Clearwater, Florida, 33765
The Ohio State University /ID# 200542
Columbus, Ohio, 43210-1257
Florida Academic Centers Research and Education /ID# 200544
Coral Gables, Florida, 33134
Psoriasis Treatment Center of Central New Jersey /ID# 200714
East Windsor, New Jersey, 08520
Deaconess Clinic Downtown /ID# 201001
Evansville, Indiana, 47713-1227
Rivergate Dermatology & Skin Care Center /ID# 201698
Goodlettsville, Tennessee, 37072-2301
Center for Clinical Studies /ID# 200582
Houston, Texas, 77004
Indiana University /ID# 200515
Indianapolis, Indiana, 46202
University of California Irvine /ID# 200902
Irvine, California, 92697-1385
Dartmouth-Hitchcock Medical Center /ID# 200918
Lebanon, New Hampshire, 03756
University of Wisconsin - Madison /ID# 204933
Madison, Wisconsin, 53715-1218
Advanced Dermatology and Skin Care Centre /ID# 213550
Mobile, Alabama, 36605-3004
Stones River Dermatology /ID# 204962
Murfreesboro, Tennessee, 37129-3194
Juva Skin and Laser Center /ID# 200997
New York, New York, 10022-3204
Eastern Virginia Med School /ID# 200994
Norfolk, Virginia, 23507-1627
Tory P Sullivan, MD PA /ID# 201174
North Miami Beach, Florida, 33162-4708
Skin Specialists, PC /ID# 200573
Omaha, Nebraska, 68144
Park Avenue Dermatology, PA /ID# 201012
Orange Park, Florida, 32073
Epiphany Dermatology of Kansas LLC /ID# 203026
Overland Park, Kansas, 66210
Alliance Dermatology and MOHs Center, PC /ID#200540
Phoenix, Arizona, 85032
Arizona Research Center, Inc. /ID# 200546
Phoenix, Arizona, 85053-4061
University of Pittsburgh MC /ID# 206057
Pittsburgh, Pennsylvania, 15260
Oregon Dermatology and Research Center /ID# 200601
Portland, Oregon, 97210
Rhode Island Hospital /ID# 200566
Providence, Rhode Island, 02903
MediSearch Clinical Trials /ID# 201006
Saint Joseph, Missouri, 64506
Advanced Clinical Research - Woseth Dermatology /ID# 213745
Salt Lake City, Utah, 84117-4209
Progressive Clinical Research /ID# 201582
San Antonio, Texas, 78229
Therapeutics Clinical Research /ID# 200593
San Diego, California, 92123
Clear Dermatology & Aesthetics Center /ID# 201257
Scottsdale, Arizona, 85255-4134
Dermatology Associates of Seattle /ID# 200717
Seattle, Washington, 98101
Dermatology Physicians of Connecticut /ID# 201004
Shelton, Connecticut, 06484-6211
Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556
Skokie, Illinois, 60077
Stanford University /ID# 200597
Stanford, California, 94305
Precision Clinical Research /ID# 208734
Sunrise, Florida, 33351-7311
J. Schwartz, MD, PLLC /ID# 202122
Troy, New York, 12180-2323
University of Arizona /ID# 201059
Tucson, Arizona, 85719
Vital Prospects Clinical Research Institute, PC /ID# 200901
Tulsa, Oklahoma, 74136-7049
AAPRI Clinical Research /ID# 221134
Warwick, Rhode Island, 02886-2876
Center for Clinical Studies - Webster TX /ID# 203186
Webster, Texas, 77598
Duplicate_Western States Clinical Research, Inc. /ID# 201702
Wheat Ridge, Colorado, 80033-2896
DuPage Medical Group /ID# 202065
Wheaton, Illinois, 60189-3801
Canada17 sites
Kirk Barber Research, CA /ID# 200329
Calgary, Alberta, T2G 1B1
Dermatology Research Institute Inc. /ID# 200341
Calgary, Alberta, T2J 7E1
Alberta DermaSurgery Centre /ID# 205674
Edmonton, Alberta, T6G 1C3
Eastern Canada Cutaneous Resea /ID# 200335
Halifax, Nova Scotia, B3H 1Z2
Lynderm Research Inc. /ID# 200338
Markham, Ontario, L3P 1X2
DermEdge Research Inc. /ID# 200337
Mississauga, Ontario, L5H 1G9
CHU Sainte-Justine /ID# 206013
Montreal, Quebec, H3T 1C5
The Centre for Clinical Trials /ID# 205404
Oakville, Ontario, L6J 7W5
Angela Montgomery Medicine Professional Corporation /ID# 212653
Ottawa, Ontario, K1H 7X3
SKIN Centre for Dermatology /ID# 200331
Peterborough, Ontario, K9J 5K2
Centre de recheche dermatologique du Quebec Metropolitain /ID# 205403
Québec, Quebec, G1V 4X7
The Center For Dermatology /ID# 205409
Richmond Hill, Ontario, L4B 1A5
Dre Angelique Gagne-Henley M.D. inc. /ID# 200330
Saint-Jérôme, Quebec, J7Z 7E2
Karma Clinical Trials /ID# 200339
St. John's, Newfoundland and Labrador, A1A 4Y3
Toronto Research Centre /ID# 205411
Toronto, Ontario, M3H 5Y8
Research Toronto /ID# 205410
Toronto, Ontario, M4W 2N4
XLR8 Medical Research /ID# 205405
Windsor, Ontario, N8W 1E6
Japan16 sites
Hiramoto skin clinic /ID# 204048
Amagasaki-shi, Hyōgo, 661-0953
Juntendo University Hospital /ID# 202888
Bunkyo-ku, Tokyo, 113-8431
Medical Corporation Matsuo Clinic /ID# 202312
Fukuoka, Fukuoka, 819-0373
Osaka Habikino Medical Center /ID# 204243
Habikino-shi, Osaka, 583-8588
Tokai University Hachioji Hospital /ID# 201711
Hachioji-shi, Tokyo, 192-0032
Hiroshima University Hospital /ID# 201914
Hiroshima, Hiroshima, 734-8551
Maruyama Dermatology Clinic /ID# 202350
Koto-ku, Tokyo, 136-0074
University Hospital Kyoto Prefectural University of Medicine /ID#258604
Kyoto, Kyoto, 602-8566
Kyoto University Hospital /ID# 201654
Kyoto, Kyoto, 606-8507
Chukyo Hospital /ID# 202311
Nagoya, Aichi-ken, 457-8510
National Hospital Organization Sagamihara National Hospital /ID# 201658
Sagamihara-shi, Kanagawa, 252-0392
Medical Corporation Kojinkai Sapporo Skin Clinic /ID#258665
Sapporo, Hokkaido, 060-0063
Tohoku University Hospital /ID# 206322
Sendai, Miyagi, 9808574
Jichi Medical University Hospital /ID# 201913
Shimotsuke-shi, Tochigi, 329-0498
Yamate Dermatological Clinic /ID# 202130
Shinjuku-ku, Tokyo, 1690075
Queens Square Medical Center dermatology allergology /ID# 203850
Yokohama, Kanagawa, 220-6208
Germany10 sites
Universitaetsklinikum Bonn /ID# 202092
Bonn, 53127
Universitaetsklinikum Frankfurt /ID# 202095
Frankfurt am Main, Hesse, 60590
TFS Trial Form Support GmbH /ID# 202096
Hamburg, 20537
Medizinische Hochschule Hannover /ID# 202098
Hanover, 30625
Universitaetsklinik Heidelberg /ID# 202097
Heidelberg, Baden-Wurttemberg, 69120
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202256
Kiel, Schleswig-Holstein, 24105
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205194
Mainz, 55131
Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202093
Munich, 81675
Universitaetsklinikum Muenster /ID# 202094
Münster, North Rhine-Westphalia, 48149
CMS3 Company for Medical Study /ID# 205195
Selters, Rhineland-Palatinate, 56242
China9 sites
Chinese PLA General Hospital /ID# 206786
Beijing, Beijing Municipality, 100853
Beijing Friendship Hospital /ID# 207434
Beijing, 100032
Xiangya Hospital Central South University /ID# 207510
Changsha, 410008
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 206728
Guangzhou, Guangdong, 510120
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 207132
Hangzhou, Zhejiang, 310006
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 207442
Hangzhou, Zhejiang, 310009
Huashan Hospital of Fudan University /ID# 207437
Shanghai, 200040
The First Hospital of China Medical University /ID# 209840
Shenyang, Liaoning, 110001
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 206669
Wuhan, Hubei, 430022
United Kingdom7 sites
NHS Tayside /ID# 202081
Dundee, Scotland, DD2 1UB
NHS Greater Glasgow and Clyde /ID# 201374
Glasgow, Scotland, G12 0XH
Leeds Teaching Hospitals NHS Trust /ID# 201106
Leeds, LS9 7TF
Barts Health NHS Trust /ID# 201044
London, London, City of, E1 2ES
Guy's and St Thomas' NHS Foundation Trust /ID# 201193
London, London, City of, SE1 9RT
Guy's and St Thomas' NHS Foundation Trust /ID# 204642
London, London, City of, SE1 9RT
Oxford University Hospitals NHS Foundation Trust /ID# 202052
Oxford, Oxfordshire, OX3 9DU
Greece6 sites
401 GSNA - 401 Army General Hospital /ID# 211963
Athens, Attica, 11525
Children's Hosp P. A. Kyriakou /ID# 217573
Athens, Attica, 11527
University General Hospital Attikon /ID# 201126
Athens, Attica, 12462
General Hospital Andreas Syggros /ID# 201123
Athens, Attica, 16121
Papageorgiou General Hospital Thessaloniki /ID# 202392
Stavroupoli (Thessalonikis), Thessaloniki, 55536
Thessaloniki Hospital of Skin and Venereal Diseases /ID# 201124
Thessaloniki, 54643
Italy6 sites
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200690
Ancona, 60126
A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200742
Catania, 95123
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 200744
Milan, 20122
Azienda Ospedaliera Universitaria Federico II /ID# 200751
Naples, 80131
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 203014
Rome, Lazio, 00168
Istituto Clinico Humanitas /ID# 200739
Rozzano, Milano, 20089
Spain6 sites
Hospital General Universitario Alicante /ID# 200873
Alicante, 03010
Hospital Santa Creu i Sant Pau /ID# 201325
Barcelona, 08041
Hospital Universitario de la Princesa /ID# 201517
Madrid, 28006
Hospital Universitario 12 de Octubre /ID# 201135
Madrid, 28041
Hospital Universitario La Paz /ID# 205438
Madrid, 28046
Hospital Universitario de Puerto Real /ID# 200875
Puerto Real, Cadiz, 11510
Australia5 sites
Fremantle Dermatology /ID# 205306
Fremantle, Western Australia, 6160
St George Dermatology & Skin Cancer Centre /ID# 204788
Kogarah, New South Wales, 2217
Royal North Shore Hospital /ID# 204639
St Leonards, New South Wales, 2065
Westmead Hospital /ID# 205682
Westmead, New South Wales, 2145
Veracity Clinical Research /ID# 204793
Woolloongabba, Queensland, 4102
France5 sites
Hopital Saint-Andre /ID# 206129
Bordeaux, 33075
AP-HM - Hopital de la Timone /ID# 206128
Marseille, Bouches-du-Rhone, 13385
Chu de Nice-Hopital L'Archet Ii /Id# 205780
Nice, Alpes-Maritimes, 06200
Polyclinique Courlancy /ID# 201537
Reims, 51100
CHRU Tours - Hopital Gatien de Clocheville /ID# 218209
Tours, Centre-Val de Loire, 37044
Hungary5 sites
Debreceni Egyetem Klinikai Kozpont /ID# 201765
Debrecen, Hajdú-Bihar, 4032
Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 217866
Debrecen, 4031
Oroshazi Korhaz /ID# 203525
Orosháza, Bekes County, 5900
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 204144
Szeged, Csongrád megye, 6725
Allergo-Derm Bakos Kft. /ID# 205361
Szolnok, 5000
Israel5 sites
HaEmek Medical Center /ID# 201958
Afula, 1834111
Soroka University Medical Center /ID# 206652
Beersheba, Southern District, 8443901
Rabin Medical Center /ID# 201959
Petah Tikva, 4941492
The Chaim Sheba Medical Center /ID# 201611
Ramat Gan, Tel Aviv, 5265601
Tel Aviv Sourasky Medical Center /ID# 201608
Tel Aviv, Tel Aviv, 6423906
Austria4 sites
Medizinische Universitaet Innsbruck /ID# 210897
Innsbruck, Tyrol, 6020
Ordensklinikum Linz GmbH Elisabethinen /ID# 209567
Linz, Upper Austria, 4010
Kepler Universitaetsklinikum GmbH /ID# 201075
Linz, Upper Austria, 4021
Medizinische Universitaet Wien /ID# 201080
Vienna, State of Vienna, 1090
Belgium4 sites
UZ Gent /ID# 202030
Ghent, Oost-Vlaanderen, 9000
UZ Brussel /ID# 203557
Jette, Brussels Capital, 1090
IMTR - Grand Hopital de Charleroi /ID# 202029
Loverval, 6280
UCL Saint-Luc /ID# 202028
Woluwe-Saint-Lambert, Brussels Capital, 1200
Czechia4 sites
Fakultni nemocnice Plzen /ID# 202044
Pilsen, 305 99
Sanatorium profesora Arenbergera /ID# 202082
Prague, 110 00
Duplicate_Vseobecna Fakultni Nemocnice /ID# 205248
Prague, 128 08
Vseobecna fakultni nemocnice v Praze /ID# 202045
Prague, 128 08
Netherlands4 sites
Academisch Medisch Centrum /ID# 202193
Amsterdam, 1105 AZ
Universitair Medisch Centrum Groningen /ID# 202195
Groningen, 9713 GZ
Erasmus Medisch Centrum /ID# 202196
Rotterdam, South Holland, 3015 GD
Universitair Medisch Centrum Utrecht /ID# 202194
Utrecht, 3584 CX
Norway4 sites
Haukeland University Hospital /ID# 201152
Bergen, Hordaland, 5021
Universitetssykehuset N-Norge, Harstad /ID# 201269
Harstad, Troms, 9406
Rikshospitalet OUS HF /ID# 201271
Oslo, 0450
Universitetssykehuset N-Norge, Tromso /ID# 201270
Tromsø, Troms, 9019
Slovakia4 sites
Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 204372
Banská Bystrica, 975 17
Univerzitna nemocnica Martin /ID# 203851
Martin, 036 01
Fakultna nemocnica s poliklinikou Nove Zamky /ID# 204240
Nové Zámky, 940 34
Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 204373
Prešov, 081 01
Sweden4 sites
Sahlgrenska University Hospital /ID# 201274
Gothenburg, Västra Götaland County, 413 46
Skane University Hospital Lund /ID# 201244
Lund, Skåne County, SE 221 41
Sodersjukhuset /ID# 201242
Stockholm, 118 83
Karolinska University Hospital /ID# 201243
Stockholm, 171 76
Ireland3 sites
South Infirmary Victoria University Hospital /ID# 201079
Cork, T12 X23H
St James Hospital /ID# 201118
Dublin, Dublin, D08 NHY1
University Hospital Waterford /ID# 201253
Waterford, X91 ER8E
Puerto Rico3 sites
Dr. Samuel Sanchez PSC /ID# 202002
Caguas, 00727
Clinical Research Puerto Rico /ID# 203644
San Juan, 00909
GCM Medical Group PSC - Hato Rey /ID# 202003
San Juan, 00917-3104
Hong Kong2 sites
Prince of Wales Hospital /ID# 205152
Hong Kong, 999077
Queen Mary Hospital /ID# 205146
Hong Kong, 999077
About this study
Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Read the detailed description
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week 260 to Week 524, and a 30-day follow-up visit. Participants who meet eligibility criteria in the Main Study will be randomly assigned in a 1:1:1 ratio to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, in combination with topical corticosteroids.
Upon completion of enrollment of 810 participants in the Main Study, a supplemental study will continue to enroll adolescent participants (Adolescent Sub-study) until a total of 180 adolescent participants are enrolled in the overall study (Main Study + Adolescent Sub-study).
Approximately 1000 participants from M16-045 or M18-891 and approximately 500 participants from M16-047 will have the opportunity to enroll into the blinded Long-Term Extension (LTE) period (Week 260 - Week 524) after reaching Week 260 in their respective studies.
Randomization for the Main Study will be stratified by Baseline disease severity (validated Investigator Global Assessment Scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the Adolescent Sub-study will be stratified by Baseline disease severity (moderate [vIGA-AD 3] versus severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).
At Week 16 of both the Main Study and the Adolescent Sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period, and participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. For the Main Study, the re-randomization will be stratified by Eczema Area and Severity Index (EASI) 50 responder status (Yes/No), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other) and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). For the Adolescent Sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).
Starting at Week 4, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary The Primary Analysis for the Main Study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the Main Study and the Adolescent Sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
- Conditions
- Atopic Dermatitis
- Being tested
- Placebo, Upadacitinib, Topical corticosteroids (TCS)
- Keywords
- Atopic Dermatitis, Upadacitinib
- Medical subject headings
- Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Tablets taken orally once a day
UpadacitinibDrug
Also called ABT-494, RINVOQ™
Tablets taken orally once a day
Topical corticosteroids (TCS)Drug
Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.
Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
| Study group | Role | What they receive |
|---|---|---|
| Placebo / Upadacitinib + Topical Corticosteroids | Placebo comparator | Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52. Receives: Drug: Placebo; Drug: Upadacitinib; Drug: Topical corticosteroids (TCS) |
| Upadacitinib 15 mg QD + Topical Corticosteroids | Experimental | Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52. Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS) |
| Upadacitinib 30 mg QD + Topical Corticosteroids | Experimental | Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52. Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS) |
| Long-Term Extension | Experimental | Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524. Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Measured: Baseline and Week 16
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:
- 0 - Clear: No inflammatory signs of AD;
- 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
- 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
- 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present;
- 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
Measured: Baseline and Week 16
Secondary outcomes (22)
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Measured: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 2
Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Measured: Baseline and Week 4
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 [none], to 3 [severe]) for redness, thickness, scratching, and lichenification.
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.
Measured: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 1
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Measured: Baseline and Week 16
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:
- 0 - Clear: No signs of AD;
- 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
- 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
- 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting;
- 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
Measured: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 4
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 4
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 2
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Measured: Baseline and Week 4
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 [none], to 3 [severe]) for redness, thickness, scratching, and lichenification.
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.
The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.
Measured: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 1
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).
The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Measured: Baseline and Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2018
- Study start9 Aug 2018
- Primary completion16 Feb 2021
- Study completion23 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,533 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03568318
- Sponsor's protocol ID
- M16-047
- Other IDs
- 2017-005126-37, 2017
- Acronym
- AD Up
- Status last verified
- Sep 2025
- First submitted
- 14 Jun 2018
- Last updated
- 23 Dec 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
- Expanded access
- Available
Publications
Silverberg JI, Prajapati VH, Abraham S, Irvine AD, Gooderham MJ, Guttman-Yassky E, Tanizaki H, Rademaker M, Chen SH, Moreira A, Ta R, Lee WJ, Eyerich K. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study. Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print.
PubMed 42530735Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3.
PubMed 40900410Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
PubMed 40875187Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.
PubMed 39441580Silverberg JI, Leshem YA, Calimlim BM, McDonald J, Litcher-Kelly L. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2023 Oct;39(10):1289-1296. doi: 10.1080/03007995.2023.2251883. Epub 2023 Sep 13.
PubMed 37691437Thyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21.
PubMed 37247226Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
PubMed 37043227Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
PubMed 36754548Silverberg JI, Simpson EL, Calimlim BM, Litcher-Kelly L, Li X, Sun X, Leshem YA. Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther (Heidelb). 2022 Dec;12(12):2817-2827. doi: 10.1007/s13555-022-00836-5. Epub 2022 Nov 4.
PubMed 36333616Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.
PubMed 35714786Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
PubMed 34023009